The widely accepted strategy of antiplatelet therapy to stem the risk of thrombosis in the months after transcatheter aortic valve replacement (TAVR) is again being challenged – this time as researchers set out to investigate the effects of a NOAC-based regimen post-TAVR in patients without atrial fibrillation. The study, called GALILEO, will be the first ...
Trial will compare rivaroxaban with standard antiplatelet treatment after TAVR
By Sunalie Silva
6 Mar 2017